Provectus Biopharmaceuticals (PVCT) 10-Q 13 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - $ / shares	6 Months Ended
	Jun. 30, 2024	Aug. 12, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	800 S. Gay Street
Entity Address, Address Line Two	Suite 1610
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37929
City Area Code	866
Local Phone Number	594-5999
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		419,906,859
Entity Information, Former Legal or Registered Name	Not Applicable
Entity Listing, Par Value Per Share	$ 0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 29,581	$ 76,576
Restricted cash	559,702	950,223
Short-term receivables	767	476
Prepaid expenses and other current assets	210,194	337,522
Total Current Assets	800,244	1,364,797
Equipment and furnishings, less accumulated depreciation of $115,455 and $110,994, respectively	7,559	12,020
Operating lease right-of-use asset	48,624	72,026
Total Assets	856,427	1,448,843
Current Liabilities:
Accounts payable	1,321,947	1,675,891
Unearned grant revenue	460,185	953,248
Other accrued expenses	3,388,425	3,240,436
Notes payable	109,862	277,815
Operating lease liability, current portion	49,975	48,077
Total Current Liabilities	8,369,500	9,016,895
Operating lease liability, non-current portion		25,299
Total Liabilities	8,369,500	9,042,194
Commitments, contingencies, and litigations (Note 12)
Stockholders’ Deficit:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,522,119 shares issued and outstanding at June 30, 2024 and December 31, 2023	419,522	419,522
Additional paid-in capital	246,156,198	244,714,967
Accumulated other comprehensive loss	(60,454)	(60,165)
Accumulated deficit	(254,041,299)	(252,690,409)
Total Stockholders’ Deficit	(7,513,073)	(7,593,351)
Total Liabilities and Stockholders’ Deficit	856,427	1,448,843
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	957	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	12,003	10,361
Nonrelated Party [Member]
Current Liabilities:
Accrued interest	62,076	22,600
Convertible notes payable	1,153,000	800,000
Related Party [Member]
Current Liabilities:
Accrued interest	89,030	123,828
Convertible notes payable	$ 1,735,000	$ 1,875,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accumulated depreciation, equipment and furnishings	$ 115,455	$ 110,994
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	419,522,119	419,522,119
Common stock, shares outstanding	419,522,119	419,522,119
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	957,100	12,374,000
Preferred stock, shares issued	956,985	12,373,247
Preferred stock, shares outstanding	956,985	12,373,247
Preferred stock, liquidation preference value	$ 1,095,556	$ 14,164,889
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized	23,042,900	11,241,000
Preferred stock, shares issued	12,002,888	10,361,097
Preferred stock, shares outstanding	12,002,888	10,361,097
Preferred stock, liquidation preference value	$ 137,408,291	$ 118,613,136

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Grant Revenue	$ 254,991	$ 161,842	$ 493,063	$ 366,867
Operating Expenses:
Research and development	472,927	434,214	1,028,462	982,607
General and administrative	576,918	527,831	706,720	966,676
Total Operating Expenses	1,049,845	962,045	1,735,182	1,949,283
Total Operating Loss	(794,854)	(800,203)	(1,242,119)	(1,582,416)
Other Income/(Expense):
Research and development tax credit	9,301	15,965	9,301	15,965
Interest expense	(61,295)	(50,824)	(118,072)	(96,065)
Total Other Expense, Net	(51,994)	(34,859)	(108,771)	(80,100)
Net Loss	$ (846,848)	$ (835,062)	$ (1,350,890)	$ (1,662,516)
Net Loss per share - basic	$ 0	$ 0	$ 0	$ 0
Net Loss per share - diluted	$ 0	$ 0	$ 0	$ 0
Weighted average number of shares - basic	419,522,119	419,497,119	419,522,119	419,497,119
Weighted average number of shares - diluted	419,522,119	419,497,119	419,522,119	419,497,119

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net Loss	$ (846,848)	$ (835,062)	$ (1,350,890)	$ (1,662,516)
Other Comprehensive Loss:
Foreign currency translation adjustments	126	(278)	(289)	(87)
Total Comprehensive Loss	$ (846,722)	$ (835,340)	$ (1,351,179)	$ (1,662,603)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series D-1 Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 12,373	$ 9,747	$ 419,497	$ 242,954,193	$ (35,679)	$ (249,588,641)	$ (6,228,510)
Balance, shares at Dec. 31, 2022	12,373,247	9,746,626	419,497,119
Conversion of 2021 Note to Series D-1 Preferred Stock		$ 18		53,992			54,010
Conversion of 2021 Note to Series D-1 Preferred Stock, shares		18,872
Net loss						(827,454)	(827,454)
Other comprehensive loss					191		191
Balance at Mar. 31, 2023	$ 12,373	$ 9,765	$ 419,497	243,008,185	(35,488)	(250,416,095)	(7,001,763)
Balance, shares at Mar. 31, 2023	12,373,247	9,765,498	419,497,119
Balance at Dec. 31, 2022	$ 12,373	$ 9,747	$ 419,497	242,954,193	(35,679)	(249,588,641)	(6,228,510)
Balance, shares at Dec. 31, 2022	12,373,247	9,746,626	419,497,119
Net loss							(1,662,516)
Balance at Jun. 30, 2023	$ 12,373	$ 9,954	$ 419,497	243,548,218	(35,766)	(251,251,157)	(7,296,881)
Balance, shares at Jun. 30, 2023	12,373,247	9,954,255	419,497,119
Balance at Mar. 31, 2023	$ 12,373	$ 9,765	$ 419,497	243,008,185	(35,488)	(250,416,095)	(7,001,763)
Balance, shares at Mar. 31, 2023	12,373,247	9,765,498	419,497,119
Conversion of 2021 Note to Series D-1 Preferred Stock		$ 189		540,033			540,222
Conversion of 2021 Note to Series D-1 Preferred Stock, shares		188,757
Net loss						(835,062)	(835,062)
Other comprehensive loss					(278)		(278)
Balance at Jun. 30, 2023	$ 12,373	$ 9,954	$ 419,497	243,548,218	(35,766)	(251,251,157)	(7,296,881)
Balance, shares at Jun. 30, 2023	12,373,247	9,954,255	419,497,119
Balance at Dec. 31, 2023	$ 12,373	$ 10,361	$ 419,522	244,714,967	(60,165)	(252,690,409)	(7,593,351)
Balance, shares at Dec. 31, 2023	12,373,247	10,361,097	419,522,119
Conversion of 2021 Note to Series D-1 Preferred Stock		$ 226		647,935			648,161
Conversion of 2021 Note to Series D-1 Preferred Stock, shares		226,474
Net loss						(504,042)	(504,042)
Other comprehensive loss					(415)		(415)
Balance at Mar. 31, 2024	$ 12,373	$ 10,587	$ 419,522	245,362,902	(60,580)	(253,194,451)	(7,449,647)
Balance, shares at Mar. 31, 2024	12,373,247	10,587,571	419,522,119
Balance at Dec. 31, 2023	$ 12,373	$ 10,361	$ 419,522	244,714,967	(60,165)	(252,690,409)	(7,593,351)
Balance, shares at Dec. 31, 2023	12,373,247	10,361,097	419,522,119
Net loss							(1,350,890)
Balance at Jun. 30, 2024	$ 957	$ 12,003	$ 419,522	246,156,198	(60,454)	(254,041,299)	(7,513,073)
Balance, shares at Jun. 30, 2024	956,985	12,002,888	419,522,119
Balance at Mar. 31, 2024	$ 12,373	$ 10,587	$ 419,522	245,362,902	(60,580)	(253,194,451)	(7,449,647)
Balance, shares at Mar. 31, 2024	12,373,247	10,587,571	419,522,119
Conversion of 2021 Note to Series D-1 Preferred Stock		$ 274		783,021			783,296
Conversion of 2021 Note to Series D-1 Preferred Stock, shares		273,691
Net loss						(846,848)	(846,848)
Other comprehensive loss					126		126
Forfeited shares of Series D Preferred Stock	$ (11,416)			11,416
Forfeited shares of Series D Preferred Stock, shares	(11,416,262)
Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock		$ 1,141		(1,141)
Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock, shares		1,141,626
Balance at Jun. 30, 2024	$ 957	$ 12,003	$ 419,522	$ 246,156,198	$ (60,454)	$ (254,041,299)	$ (7,513,073)
Balance, shares at Jun. 30, 2024	956,985	12,002,888	419,522,119

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows From Operating Activities:
Net loss	$ (1,350,890)	$ (1,662,516)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense	23,402	22,272
Depreciation	4,461	4,461
Changes in operating assets and liabilities
Short term receivables	(299)	(1,366)
Prepaid expenses and other current assets	127,328	314,165
Accounts payable	(353,763)	(104,704)
Unearned grant revenue	(493,063)	(366,866)
Other accrued expenses	148,011	483,019
Operating lease liability	(23,401)	(21,597)
Accrued interest	111,134	91,239
Net Cash Used In Operating Activities	(1,807,080)	(1,241,893)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	353,000
Proceeds from issuance of convertible notes payable - related parties	1,285,000	1,325,000
Repayment of short-term note payable	(167,953)	(152,856)
Repayment of 2021 convertible note payable - related party	(100,000)
Proceeds from exercise of warrants
Net Cash Provided By Financing Activities	1,370,047	1,172,144
Effect of exchange rates on cash and restricted cash	(483)	(2,799)
Net Decrease In Cash and Restricted Cash	(437,516)	(72,548)
Cash and Restricted Cash, Beginning of Period	1,026,799	1,431,707
Cash and Restricted Cash, End of Period	589,283	1,359,159
Cash	29,581	176,010
Restricted cash	559,702	1,183,149
Supplemental Disclosures of Cash Flow Information:
Interest
Income taxes
Non-cash investing and financing activities:
Conversion of 2021 Notes and related accrued interest to Series D-1 Preferred Stock		594,232
Conversion of 2022 Notes and related accrued interest to Series D-1 Preferred Stock	1,431,457
Forfeited shares of Series D Preferred Stock	(11,416)
Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock	1,141
Purchase of insurance policies financed by short-term note payable		$ (61,735)

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of synthetic small molecule halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal sodium (“RBS”). The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (“API”) in the drug candidates of our current clinical development programs and the non-clinical formulations of our current non-clinical proof-of-concept in vivo The Company believes that RBS targets disease in a bifunctional multi-modal manner. Direct contact by RBS may lead to cell death or repair, depending on the disease being treated and the concentration of RBS utilized in the treatment formulation, by one or more targeting mechanisms. Multivariate innate and adaptive immune activation, signaling, and response may follow that may manifest as stimulatory, inhibitory, or both. The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry at ClinicalTrials.gov. The Company believes that it is the first and only entity to date to make pharmaceutical-grade RBS successfully, reproducibly, and consistently at a purity of nearly 100%. The Company’s small molecule medical science platform comprises several different drug candidates and non-clinical targets using different concentrations delivered by different routes of administration specific to each disease area and/or disease indication, including: ● Clinical development programs in oncology (intratumoral administration), dermatology (topical), and ophthalmology (topical), ● Proof-of-concept in vivo ● Early discovery programs ( in vitro Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2023 filed with the SEC on March 28, 2024. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s cash and restricted cash were $ 589,283 559,702 7,569,256 7,652,098 1,350,890 1,662,516 1,807,080 1,241,893 The Company plans to access capital resources through possible public or private equity offerings, including the 2024 financing (see Note 13), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although there can be no assurance that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, there can be no assurance that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2024 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, there can be no assurance that it will be able to obtain funds on commercially acceptable terms, or complete additional financing in a timely manner. Any such financing may result in significant dilution to stockholders. These factors raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of liabilities that may be necessary should we be unable to continue as a going concern. Our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate our continuation as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Since the date the Company’s December 31, 2023 consolidated financial statements were issued in its 2023 Annual Report on March 28, 2024, there have been no material changes to the Company’s significant accounting policies. Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, accrued liabilities, and the valuation allowance related to the Company’s deferred tax assets. Restricted Cash Restricted cash consists of a grant award received from the State of Tennessee. Restricted cash available as of June 30, 2024 is $ 559,702 Cash Concentrations Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 339,283 776,799 Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares June 30, 2024 2023 Warrants - 475,000 Options 3,225,000 3,425,000 Convertible preferred stock 120,985,865 111,915,797 2021 unsecured convertible notes 505,746 2,022,750 2022 unsecured convertible notes 10,113,074 7,485,783 Total potentially dilutive shares 134,829,685 125,324,330 Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 “ Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Other Accrued Expenses

Other Accrued Expenses	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
Other Accrued Expenses	4. Other Accrued Expenses The following table summarizes the other accrued expenses at June 30, 2024 and December 31, 2023: Schedule of Other Accrued Expenses June 30, December 31, 2024 2023 Accrued payroll and taxes $ 1,037,118 $ 719,460 Accrued vacation 109,706 92,985 Accrued directors’ fees 2,054,339 2,330,589 Accrued other expenses 187,262 97,402 Total other accrued expenses $ 3,388,425 $ 3,240,436

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Convertible Notes Payable	5. Convertible Notes Payable The following summarizes convertible notes payable activity during the six months ended June 30, 2024: 2021 Financing Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ - $ 200,000 $ 200,000 Repayment - (100,000 ) (100,000 ) Balance as of June 30, 2024 $ - $ 100,000 $ 100,000 2022 Financing Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ 800,000 $ 1,675,000 $ 2,475,000 Issued 353,000 1,285,000 1,638,000 Conversion - (1,325,000 ) (1,325,000 ) Balance as of June 30, 2024 $ 1,153,000 $ 1,635,000 $ 2,788,000 Balance $ 1,153,000 $ 1,635,000 $ 2,788,000 On July 11, 2024, the Board approved the closure of the 2022 Financing. Through June 30, 2024, the Company received 2022 Notes proceeds in the aggregate amount of $ 4,865,500 3,637,500 For further details on the terms of the 2021 and 2022 Notes, refer to our Form 10-K as filed with the SEC on March 28, 2024. 2024 Repayment of 2021 Notes During the six months ended June 30, 2024, the Company repaid $ 100,000 100,000 44,744 2024 Conversions of 2022 Notes into Preferred Stock During the three months ended June 30, 2024, principal and interest in the aggregate amount of $ 783,296 273,691 2.862 During the six months ended June 30, 2024, principal and interest in the aggregate amount of $ 1,431,457 500,165 2.862

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of June 30, 2024 and December 31, 2023, the balance of the note payable was $ 109,862 277,815

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions During the three months ended June 30, 2024 and 2023, the Company had consulting fees of $ 0 and $ 63,600 to Mr. Bruce Horowitz (Capital Strategists) for services rendered. During the six months ended June 30, 2024 and 2023, the Company had consulting fees of $ 63,600 127,200 250,000 June 27, 2024, the Company paid $ 258,000 outstanding consulting fees. Mr. Horowitz waived the amount of $ 469,000 due to him in directors’ fees. See Note 5 for details of other related party transactions. Directors’ fees incurred during the three months ended June 30, 2024 and 2023, were $ 77,500 96,250 173,750 192,500 2,054,339 2,330,589

Stockholders_ Deficit

Stockholders’ Deficit	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Stockholders’ Deficit	8. Stockholders’ Deficit Preferred Stock During the three months ended June 30, 2024, the Company issued 273,691 725,000 58,294 During the six months ended June 30, 2024, the Company issued 500,165 1,325,000 106,457 On June 21, 2024, the Board of Directors approved the conversion of 11,416,242 1,141,626 shares of Series D-1 Preferred shares. Number of Preferred Shares On June 24, 2024, the Company filed an amended Series D Certificate of Designation to decrease the authorized shares from 12,374,000 957,100 9,441,000 23,042,900 2024 Equity Compensation Plan At the shareholder meeting held on June 20, 2024, the proposal for the new 2024 Equity Compensation Plan was approved. The approval gives the Company authority to grant Options and award Restricted Stock under the 2024 Equity Compensation Plan for up to 100,000,000 15 Options During the three and six months ended June 30, 2024 and 2023, the Company did not have any issuances, grants, or exercises of options. The following table summarizes option activities during the six months ended June 30, 2024: Schedule of Option Activity Weighted Average Weighted Average Remaining Aggregate Intrinsic Shares Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2024 3,225,000 $ 0.27 $ - Expired - - Outstanding and exercisable at June 30, 2024 3,225,000 $ 0.27 1.40 $ - The following table summarizes information about options outstanding and exercisable at June 30, 2024: Summary of Stock Options Outstanding Exercise Price Outstanding and Exercisable Weighted Average Remaining Contractual Life Intrinsic Value $ 0.12 2,425,000 1.40 $ 14,550 $ 0.29 100,000 1.40 $ - $ 0.75 550,000 1.50 $ - $ 0.88 150,000 0.10 $ - 3,225,000 1.40 $ 14,550 Warrants During the three and six months ended June 30, 2024 and 2023, the Company did not have any issuances, grants, or exercises of warrants. The following table summarizes warrant activities during the six months ended June 30, 2024: Schedule of Warrant Activity Number of Weighted Average Weighted Average Remaining Aggregate Intrinsic Warrants Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2024 412,500 $ 1.07 Expired (412,500 ) 1.07 Outstanding and exercisable at June 30, 2024 - $ - - $ - Annual Stockholder Meeting Proposals The Company held its annual meeting of stockholders on June 20, 2024. Stockholders authorized the Company’s board of directors (the “Board”) to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 1-for-50

Leases

Leases	6 Months Ended
	Jun. 30, 2024
Leases
Leases	9. Leases On June 18, 2022, the Company leased 2,700 three years 4,053 4,278 Total operating lease expense for the three months ended June 30, 2024 was $ 13,002 8,668 4,334 12,672 8,448 4,224 Total operating lease expense for the six months ended June 30, 2024 was $ 25,844 17,229 8,615 26,179 17,453 8,726 A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For the Six Months Ended June 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 23,402 $ 21,597 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 1 year 2 years Weighted Average Discount Rate Operating leases 5.0 % 5.0 % Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2024 were as follows: Future Minimum Payments Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2024 $ 25,669 2025 25,669 Total lease payments 51,338 Less: amount representing imputed interest (1,363 ) Present value of lease liability 49,975 Less: current portion (49,975 ) Lease liability, non-current portion $ -

Grants

Grants	6 Months Ended
	Jun. 30, 2024
Grants
Grants	10. Grants On October 25, 2021, the Company received a grant award of $ 2,500,000 As of June 30, 2024 and December 31, 2023, $ 460,185 953,248 254,991 493,063 161,842 366,867

License Transactions

License Transactions	6 Months Ended
	Jun. 30, 2024
License Transactions
License Transactions	11. License Transactions In the third quarter of 2019, the Company entered into a dialog with Bascom Palmer Eye Institute (“BPEI”) regarding collaboration on BPEI’s ophthalmic photodynamic antimicrobial therapy (“PDAT”) using the Company’s pharmaceutical-grade RBS. On February 16, 2022, and later amended on May 11, 2022, the Company entered into an option agreement with the University of Miami (“UM”) for an exclusive worldwide license of intellectual property (“IP”) developed by the Ophthalmic Biophysics Center (“OBC”) of BPEI that included the use of OBC’s PDAT medical device in combination with formulations of the Company’s pharmaceutical-grade RBS for the treatment of bacterial, fungal, and viral infections of the eye. The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company paid $5,000 for the option that expires on May 31, 2023; agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP; and entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis. On March 21, 2024, the Company entered into an exclusive worldwide license for the IP. Details of the license agreement are reported in the Company’s Current Report on Form 8-K filed with the SEC on March 27, 2024.

Commitments, Contingencies and

Commitments, Contingencies and Litigation	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	12. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising from the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s condensed consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. 2024 Financing On July 11, 2024, the Board approved a Financing Term Sheet (the “2024 Term Sheet”), which set forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $ 10,000,000 Pursuant to the 2024 Term Sheet, the 2024 Notes (defined below) will convert into shares of the Company’s Series D-1 Preferred Stock twelve months after the issue date of a 2024 Note, subject to certain exceptions. The 2024 Financing will be in the form of an unsecured convertible loan (the “2024 Loan”) from the investors (the “2024 Loan Investors”) and evidenced by convertible promissory notes (individually, a “2024 Note” and collectively, the “2024 Notes”). In addition to customary provisions, the 2024 Notes will contain the following provisions: (i) The 2024 Loan will bear interest at the rate of eight percent ( 8 (ii) In the event there is a change of control of the Board, the term of the 2024 Notes will be accelerated and all amounts due under the 2024 Notes may be immediately due and payable at the 2024 Loan Investors’ option; (iii) The outstanding principal amount and interest payable under the 2024 Loan may be convertible at the 2024 Loan Investors’ option into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $ 2.8620 10 (iv) The outstanding principal amount and interest payable under the 2024 Loan will be automatically convertible into shares of the Company’s Series D-1 Preferred Stock twelve (12) months after the issue date of a 2024 Note at a price per share equal to $ 2.8620 For further details on the terms of the 2024 Financing and the details of the 2024 Notes, refer to our Form 8-K as filed with the SEC on July 17, 2024. Convertible Notes Payable Subsequent to June 30, 2024, the Company entered into 2024 Notes with a related party investor (Executive Officer) in the aggregate principal amount of $ 215,000 Series D-1 Preferred Stock Subsequent to June 30, 2024, principal and interest in the aggregate amount of $ 972,600 339,833 2.862 Subsequent to June 30, 2024, a holder of 38,474 384,740

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, accrued liabilities, and the valuation allowance related to the Company’s deferred tax assets.
Restricted Cash	Restricted Cash Restricted cash consists of a grant award received from the State of Tennessee. Restricted cash available as of June 30, 2024 is $ 559,702
Cash Concentrations	Cash Concentrations Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 339,283 776,799
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares June 30, 2024 2023 Warrants - 475,000 Options 3,225,000 3,425,000 Convertible preferred stock 120,985,865 111,915,797 2021 unsecured convertible notes 505,746 2,022,750 2022 unsecured convertible notes 10,113,074 7,485,783 Total potentially dilutive shares 134,829,685 125,324,330
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 “ Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares June 30, 2024 2023 Warrants - 475,000 Options 3,225,000 3,425,000 Convertible preferred stock 120,985,865 111,915,797 2021 unsecured convertible notes 505,746 2,022,750 2022 unsecured convertible notes 10,113,074 7,485,783 Total potentially dilutive shares 134,829,685 125,324,330

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
Schedule of Other Accrued Expenses	The following table summarizes the other accrued expenses at June 30, 2024 and December 31, 2023: Schedule of Other Accrued Expenses June 30, December 31, 2024 2023 Accrued payroll and taxes $ 1,037,118 $ 719,460 Accrued vacation 109,706 92,985 Accrued directors’ fees 2,054,339 2,330,589 Accrued other expenses 187,262 97,402 Total other accrued expenses $ 3,388,425 $ 3,240,436

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ - $ 200,000 $ 200,000 Repayment - (100,000 ) (100,000 ) Balance as of June 30, 2024 $ - $ 100,000 $ 100,000 2022 Financing Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ 800,000 $ 1,675,000 $ 2,475,000 Issued 353,000 1,285,000 1,638,000 Conversion - (1,325,000 ) (1,325,000 ) Balance as of June 30, 2024 $ 1,153,000 $ 1,635,000 $ 2,788,000 Balance $ 1,153,000 $ 1,635,000 $ 2,788,000

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Option Activity	The following table summarizes option activities during the six months ended June 30, 2024: Schedule of Option Activity Weighted Average Weighted Average Remaining Aggregate Intrinsic Shares Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2024 3,225,000 $ 0.27 $ - Expired - - Outstanding and exercisable at June 30, 2024 3,225,000 $ 0.27 1.40 $ -
Summary of Stock Options Outstanding	The following table summarizes information about options outstanding and exercisable at June 30, 2024: Summary of Stock Options Outstanding Exercise Price Outstanding and Exercisable Weighted Average Remaining Contractual Life Intrinsic Value $ 0.12 2,425,000 1.40 $ 14,550 $ 0.29 100,000 1.40 $ - $ 0.75 550,000 1.50 $ - $ 0.88 150,000 0.10 $ - 3,225,000 1.40 $ 14,550
Schedule of Warrant Activity	The following table summarizes warrant activities during the six months ended June 30, 2024: Schedule of Warrant Activity Number of Weighted Average Weighted Average Remaining Aggregate Intrinsic Warrants Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2024 412,500 $ 1.07 Expired (412,500 ) 1.07 Outstanding and exercisable at June 30, 2024 - $ - - $ -

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Leases
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For the Six Months Ended June 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 23,402 $ 21,597 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 1 year 2 years Weighted Average Discount Rate Operating leases 5.0 % 5.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2024 were as follows: Future Minimum Payments Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2024 $ 25,669 2025 25,669 Total lease payments 51,338 Less: amount representing imputed interest (1,363 ) Present value of lease liability 49,975 Less: current portion (49,975 ) Lease liability, non-current portion $ -

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and restricted cash	$ 589,283				$ 589,283
Restricted cash	559,702		$ 1,183,149		559,702	$ 1,183,149
Working capital deficiency	7,569,256				7,569,256		$ 7,652,098
Net loss	$ (846,848)	$ (504,042)	$ (835,062)	$ (827,454)	(1,350,890)	(1,662,516)
Net cash used in operations					$ 1,807,080	$ 1,241,893

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	134,829,685	125,324,330
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		475,000
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,225,000	3,425,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	120,985,865	111,915,797
2021 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	505,746	2,022,750
2022 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	10,113,074	7,485,783

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Restricted cash	$ 559,702	$ 950,223
Insured limits	250,000
Cash in excess FDIC insured amount	$ 339,283	$ 776,799

Schedule of Other Accrued Expen

Schedule of Other Accrued Expenses (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued payroll and taxes	$ 1,037,118	$ 719,460
Accrued vacation	109,706	92,985
Accrued directors’ fees	2,054,339	2,330,589
Accrued other expenses	187,262	97,402
Total other accrued expenses	$ 3,388,425	$ 3,240,436

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details)	6 Months Ended
	Jun. 30, 2024 USD ($)
2021 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	$ 200,000
Repayment	(100,000)
Balance	100,000
2021 Convertible Notes Payable [Member] | Nonrelated Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024
Repayment
Balance
2021 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	200,000
Repayment	(100,000)
Balance	100,000
2022 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	2,475,000
Balance	2,788,000
Issued	1,638,000
Conversion	(1,325,000)
2022 Convertible Notes Payable [Member] | Nonrelated Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	800,000
Balance	1,153,000
Issued	353,000
Conversion
2022 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	1,675,000
Balance	1,635,000
Issued	1,285,000
Conversion	$ (1,325,000)

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	3 Months Ended	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares
2022 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Proceeds from notes		$ 4,865,500
2022 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Proceeds from notes		3,637,500
2024 Repayments of 2021 Notes [Member]
Short-Term Debt [Line Items]
Repaid Principal		100,000
Principal		100,000
Interest		44,744
2024 Conversions of 2022 Notes [Member] | Series D-1 Convertible Preferred Stock [Member]
Short-Term Debt [Line Items]
Aggregate amount	$ 783,296	$ 1,431,457
Number of shares | shares	273,691	500,165
Conversion price per share | $ / shares	$ 2.862	$ 2.862

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Note payable	$ 109,862	$ 277,815

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)			3 Months Ended		6 Months Ended
	Jun. 27, 2024	Mar. 26, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Director fees			$ 77,500	$ 96,250	$ 173,750	$ 192,500
Accrued director fees			2,054,339		2,054,339		$ 2,330,589
Mr. Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Consulting fees			$ 0	$ 63,600	$ 63,600	$ 127,200
Mr Horowitz [Member]
Related Party Transaction [Line Items]
Consulting fees paid	$ 258,000	$ 250,000
Waived director fees	$ 469,000

Schedule of Option Activity (De

Schedule of Option Activity (Details)	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of options outstanding and exercisable, beginning balace | shares	3,225,000
Weighted average exercise price outstanding and exercisable, beginning balance | $ / shares	$ 0.27
Intrinsic Value, Outstanding | $
Stock options, expired | shares
Weighted average exercise price, expired | $ / shares
Number of options outstanding and exercisable, ending balance | shares	3,225,000
Weighted average exercise price outstanding and exercisable, ending balance | $ / shares	$ 0.27
Weighted Average Remaining Contractual Life, Exercisable	1 year 4 months 24 days
Intrinsic Value, Outstanding | $

Summary of Stock Options Outsta

Summary of Stock Options Outstanding (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.27	$ 0.27
Outstanding	3,225,000	3,225,000
Weighted Average Remaining Contractual Life, Exercisable	1 year 4 months 24 days
Intrinsic Value, Outstanding
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding	3,225,000
Exercisable	3,225,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 4 months 24 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 4 months 24 days
Intrinsic Value, Outstanding	$ 14,550
Intrinsic Value, Exercisable	$ 14,550
Range One [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.12
Exercise Price, Exercisable	$ 0.12
Outstanding	2,425,000
Exercisable	2,425,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 4 months 24 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 4 months 24 days
Intrinsic Value, Outstanding	$ 14,550
Intrinsic Value, Exercisable	$ 14,550
Range Two [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.29
Exercise Price, Exercisable	$ 0.29
Outstanding	100,000
Exercisable	100,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 4 months 24 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 4 months 24 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Three [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.75
Exercise Price, Exercisable	$ 0.75
Outstanding	550,000
Exercisable	550,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 6 months
Weighted Average Remaining Contractual Life, Exercisable	1 year 6 months
Intrinsic Value, Exercisable
Range Four [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.88
Exercise Price, Exercisable	$ 0.88
Outstanding	150,000
Exercisable	150,000
Weighted Average Remaining Contractual Life, Outstanding	1 month 6 days
Weighted Average Remaining Contractual Life, Exercisable	1 month 6 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Equity [Abstract]
Warrants outstanding and exercisable, beginning balance | shares	412,500
Weighted average exercise price outstanding and exercisable, beginning balance | $ / shares	$ 1.07
Warrants, forfeited | shares	(412,500)
Weighted average exercise price, forfeited | $ / shares	$ 1.07
Warrants outstanding and exercisable, ending balance | shares
Weighted average exercise price outstanding and exercisable, ending balance | $ / shares
Aggregate intrinsic value | $

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)			3 Months Ended				6 Months Ended
	Jun. 21, 2024	Jun. 20, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized			25,000,000				25,000,000	25,000,000
2024 Equity Compensation Plan [Member]
Class of Stock [Line Items]
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		100,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Plan Modification, Description and Terms		15
Series D-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	23,042,900	9,441,000	23,042,900				23,042,900	11,241,000
Reverse stock split		1-for-50
Series D-1 Convertible Preferred Stock [Member] | 2022 Notes [Member]
Class of Stock [Line Items]
Issuance of stock, shares			273,691				500,165
Conversion of principal			$ 725,000				$ 1,325,000
Conversion of accrued interest			$ 58,294				$ 106,457
Series D Preferred Stock [Member] | Board of Directors Chairman [Member]
Class of Stock [Line Items]
Conersion of stock, shares	11,416,242
Series D-1 Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	1,141,626		273,691	226,474	188,757	18,872
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	957,100	12,374,000	957,100				957,100	12,374,000
Reverse stock split		1-for-10

Schedule of Right-of-use Assets

Schedule of Right-of-use Assets and Liabilities (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Leases
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 23,402	$ 21,597
Right-of-use assets obtained in exchange for lease obligations: Operating leases
Weighted Average Remaining Lease Term: Operating leases	1 year	2 years
Weighted Average Discount Rate: Operating leases	5%	5%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Non-cancellable Lease (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Leases
2024	$ 25,669
2025	25,669
Total lease payments	51,338
Less: amount representing imputed interest	(1,363)
Present value of lease liability	49,975
Less: current portion	(49,975)	$ (48,077)
Lease liability, non-current portion		$ 25,299

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 18, 2022 ft²
Research and Development Expense [Member]
Operating lease, expense	$ 8,668	$ 8,448	$ 17,229	$ 17,453
General and Administrative Expense [Member]
Operating lease, expense	4,334	4,224	8,615	8,726
Property Subject to Operating Lease [Member]
Operating lease, expense	$ 13,002	$ 12,672	25,844	$ 26,179
Knoxville, Tennessee [Member]
Area of land | ft²					2,700
Lessee, operating lease, term of contract					3 years
Knoxville, Tennessee [Member] | Minimum [Member]
Rent expenses per month			4,053
Knoxville, Tennessee [Member] | Maximum [Member]
Rent expenses per month			$ 4,278

Grants (Details Narrative)

Grants (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Oct. 25, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Grants
Proceeds from grant	$ 2,500,000
Deferred revenue current		$ 460,185		$ 460,185		$ 953,248
Revenue		$ 254,991	$ 161,842	$ 493,063	$ 366,867

License Transactions (Details N

License Transactions (Details Narrative)	6 Months Ended
	Jun. 30, 2024
License Transactions
License transaction description	The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company paid $5,000 for the option that expires on May 31, 2023; agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP; and entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Jul. 18, 2024	Jul. 01, 2024	Jul. 11, 2024
Subsequent Event [Line Items]
Principal amount		$ 215,000
Common Stock [Member]
Subsequent Event [Line Items]
Number of stock converted		384,740
Series D-1 Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of stock converted		38,474
2024 Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Maximum financing amount			$ 10,000,000
Loan interest rate	8%
2024 Convertible Notes Payable [Member] | Series D-1 Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Convertible shares	10
2024 Convertible Notes Payable [Member] | Investors [Member] | Series D-1 Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Share price per share	$ 2.8620
Conversion price	$ 2.8620
2022 Note [Member] | Series D-1 Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion price		$ 2.862
Conversion of principal and interest		$ 972,600
Number of stock converted		339,833